Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma

Authors

Ute Bartels, The Hospital for Sick Children, Toronto, ON
Johannes Wolff, The Hospital for Sick Children, Toronto, ON
Lia Gore, The Hospital for Sick Children, Toronto, ON
Ira Dunkel, The Hospital for Sick Children, Toronto, ON
Stephen Gilheeney, The Hospital for Sick Children, Toronto, ON
Roger J. Packer, George Washington UniversityFollow
+12 additional authors

Document Type

Journal Article

Publication Date

11-2014

Journal

Neuro-Oncology

Volume

16

Issue

11

Inclusive Pages

1554-1559

Keywords

Antibodies, Monoclonal, Humanized--therapeutic use; Brain Stem Neoplasms--drug therapy; Glioma--drug therapy; Neoplasm Recurrence, Local--drug therapy

APA Citation

Bartels, U., Wolff, J., Gore, L., Dunkel, I., Gilheeney, S., et al. (2014). Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma. Neuro-Oncology, 16(11), 1554-1559.

Peer Reviewed

1